9 July 2019 - The UK is to try out a subscription-style payment model aimed at incentivising pharma and biotech companies to develop new drugs needed to tackle resistant infections.

Resistant bacteria already cause more than 700,000 deaths globally every year, a trend exacerbated by misuse of antibiotics in some regions.

The UK government has taken a lead among nations in addressing the growing dangers of ‘superbugs’ and antimicrobial resistance with the need for new classes of antimicrobials one of the main action points.

Read PM Live article